Articles related to IMMUNOTHERAPY

Physicians should be acutely aware of the heightened risk of neuroinvasive arboviral infections in patients treated with rituximab, necessitating a shift towards molecular diagnostic testing for timely and accurate detection.

Recent studies have highlighted the effectiveness of ruxolitinib in managing steroid-refractory chronic graft-vs-host disease, showcasing a significant improvement in overall response rates and failure-free survival compared to standard therapies.

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

ESMO Congress 2023 unveils groundbreaking advances in mUC treatments, emphasizing novel therapeutic combinations and the critical role of personalized medicine in improving patient outcomes.

In a recent study, researchers found that, although pembrolizumab increased the pathological complete response in gastric cancer patients, it did not significantly improve event-free survival.

At ECTRIMS-ACTRIMS 2023, pivotal studies like the OLIKOS and MIRANTIBUS trials have highlighted the evolving dynamics in MS treatment, particularly emphasizing the shift towards more patient-centric and effective therapeutic approaches.